Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.

Zarrabi K, Wu S. Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. Oncology. 2018; 94(5):259-273.

View in: PubMed

Alanine Transaminase
Antibodies, Monoclonal
Antineoplastic Agents
Aspartate Aminotransferases
Chemical and Drug Induced Liver Injury
Clinical Trials as Topic
Humans
Immunotherapy
Liver
Neoplasms
Risk Factors

Kevin Zarrabi

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement